atpD gene sequencing, multidrug resistance traits, virulence-determinants, and antimicrobial resistance genes of emerging XDR and MDR-Proteus mirabilis

Abdelazeem M. Algammal, Hany R. Hashem, Khyreyah J. Alfifi, Helal F. Hetta, Norhan S. Sheraba, Hazem Ramadan & Reham M. El-Tarabili

Proteus mirabilis is a common opportunistic pathogen causing severe illness in humans and animals. To determine the prevalence, antibiogram, biofilm-formation, screening of virulence, and antimicrobial resistance genes in P. mirabilis isolates from ducks; 240 samples were obtained from apparently healthy and diseased ducks from private farms in Port-Said Province, Egypt. The collected samples were examined bacteriologically, and then the recovered isolates were tested for atpD gene sequencing, antimicrobial susceptibility, biofilm-formation, PCR detection of virulence, and antimicrobial resistance genes. The prevalence of P. mirabilis in the examined samples was 14.6% (35/240). The identification of the recovered isolates was confirmed by the atpD gene sequencing, where the tested isolates shared a common ancestor. Besides, 94.3% of P. mirabilis isolates were biofilm producers. The recovered isolates were resistant to penicillins, sulfonamides, β-Lactam-β-lactamase-inhibitor-combinations, tetracyclines, cephalosporins, macrolides, and quinolones. Using PCR, the retrieved strains harbored atpD, ureC, rsbA, and zapA virulence genes with a prevalence of 100%, 100%, 94.3%, and 91.4%, respectively. Moreover, 31.4% (11/35) of the recovered strains were XDR to 8 antimicrobial classes that harbored blaTEM, blaOXA-1α, blaCTX-M, tetA, and sul1 genes. Besides, 22.8% (8/35) of the tested strains were MDR to 3 antimicrobial classes and possessed blaTEM, tetA, and sul1 genes. Furthermore, 17.1% (6/35) of the tested strains were MDR to 7 antimicrobial classes and harbored blaTEM, blaOXA-1α, blaCTX-M, tetA, and sul1 genes. Alarming, three strains were carbapenem-resistant that exhibited PDR to all the tested 10 antimicrobial classes and shared blaTEM, blaOXA-1α, blaCTX-M, tetA, and sul1 genes. Of them, two strains harbored the blaNDM-1 gene, and one strain carried the blaKPC gene. In brief, to the best of our knowledge, this is the first study demonstrating the emergence of XDR and MDR-P. mirabilis in ducks. Norfloxacin exhibited promising antibacterial activity against the recovered XDR and MDR-P. mirabilis. The emergence of PDR, XDR, and MDR-strains constitutes a threat alarm that indicates the complicated treatment of the infections caused by these superbugs.

The genus Proteus includes Gram-negative, moderate-sized, non-sporulated, and motile rods. Proteus mirabilis is one of the most prevalent Proteus species. P. mirabilis normally inhabits the intestinal tract of both humans and animals.

1Department of Bacteriology, Immunology, and Mycology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt. 2Department of Microbiology and Immunology, Faculty of Pharmacy, Fayoum University, Fayoum 63514, Egypt. 3Department of Biology, Faculty of Science, Tabuk University, Tabuk 7149, Saudi Arabia. 4Department of Medical Microbiology and Immunology, Faculty of Medicine, Assuit University, Assuit 71515, Egypt. 5VACSERA, the Holding Company for Biological Products and Vaccines, Giza 12511, Egypt. 6Hygiene and Zoonoses Department, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt. *email: abdelazeem.algammal@gmail.com
animals as normal flora. Besides, it’s a ubiquitous environmental microorganism widely distributed in nature. 
P. mirabilis is known as an opportunistic bacterial pathogen that incriminated in community-acquired infections, food-borne infections, serious nosocomial infections, and urinary tract infections in humans. Furthermore, several recent studies proved the existence of P. mirabilis in animals and poultry. The molecular typing of P. mirabilis from human and animal origins revealed that the animal strains could be transmitted to humans.

The emergence of multidrug-resistant bacterial pathogens is reflected as a public health risk. Several investigations reported the occurrence of MDR pathogens from different origins including humans, animals, birds, fish, and food. The emergence of extended-spectrum β-lactam resistant Proteus species had been reported for the first time in 1987 that is considered a thoughtful public health concern globally. Besides, the existence of MDR-Proteus species was reported in previous studies.

The antimicrobial resistance genes could be transmitted to P. mirabilis from other resistant pathogens in the environment and the gastrointestinal tract, especially the extended-spectrum β-lactamase genes including; blaTEM gene: encoded for penicillins-resistance, blaCTX gene: encoded for cephalosporins-resistance, blaNDM1 gene: encoded for carbapenem-resistance, and blaOXA-1 gene: encoded for piperacillin and cephalosporins-resistance. P. mirabilis is known as a common biofilm producer. The bacterial biofilm protects the bacteria from the phagocytic cells, the environmental stresses, and different antimicrobial agents. Moreover, it is considered a frequent source of infection.

PCR is a rapid and specific reliable epidemiological tool used for screening virulence and antimicrobial resistance genes in certain bacterial pathogens. The atpD gene is one of the most conserved genes in Proteus species that encodes for ATP synthase β-subunit. The pathogenicity of P. mirabilis is regulated by several virulence determinants that are controlled by multiple virulence genes such as ureC, zapA, and rsbA virulence genes. The rsbA gene is responsible for swarming modulation in Proteus species. Moreover, the ureC gene is the principal gene responsible for urease enzyme production that plays a major role in stone formation in kidneys or bladder during urinary tract infections. Furthermore, the zapA gene is encoded for protease production, especially IgA protease.

This study is aimed to investigate the prevalence, atpD gene sequencing, antibiogram, PCR detection of virulence genes (ureC, zapA, and rsbA), and antimicrobial resistance genes (blaTEM, blaCTX, blaNDM1, blaKPC, blaOXA1, sul1, and tetA) of emerging P. mirabilis in ducks.

### Material and methods

#### Animal ethics.

The study was carried out in compliance with the ARRIVE guidelines. All methods were performed according to relevant guidelines and regulations. Handling of birds and all the experimental protocols conducted by well-trained scientists and were approved by the Animal Ethics Review Committee of Suez Canal University (AERC-SCU), Egypt.

#### Sampling.

Approximately, 240 specimens were obtained from apparently healthy (n = 40) and diseased ducks (n = 40) from private duck commercial farms (Muscovy duck with average age 70 days) at Port-Said Province, Egypt (From May 2020 to August 2020). Tracheal and cloacal swabs were collected from live birds, while the internal organs were collected separately under complete aseptic conditions from freshly dead and slaughtered ducks as illustrated in Table 1. Diseased ducks exhibited diarrhea and respiratory manifestations. Specimens were collected in peptone water (Oxoid, UK) and rapidly transmitted to the lab as soon as possible for bacteriological examination.

### Table 1.

| Types of samples | Duck condition | Apparently healthy n = 40 | Diseased ducks n = 40 |
|------------------|----------------|-------------------------|---------------------|
|                  | Live n = 20    | Freshly slaughtered n = 20 | Live n = 20 Dead n = 20 |
| Tracheal swabs   | 20 –          | 20                       |                     |
| Cloacal swabs    | 20 –          | 20                       |                     |
| Liver            | – 20          | – 20                      |                     |
| Heart            | 20 –          | – 20                      |                     |
| Lung             | – 20          | – 20                      |                     |
| Gizzard          | 20 –          | – 20                      |                     |
| Sub-total        | 80            | 80                       | 40 40               |
| Total            | 240           |                          |                     |
by Quinn24. Moreover, the identification of hemolytic activity, morphological characteristics using Gram's-staining, and biochemical characters as described in Table 2. The oligonucleotides sequences and thermal-cycling conditions of PCR assay.

Table 2. The oligonucleotides sequences and thermal-cycling conditions of PCR assay.

| Genes       | Oligonucleotides sequences                  | Amplified product (bp) | PCR conditions (35 cycles) | References |
|-------------|--------------------------------------------|------------------------|----------------------------|------------|
| atpD        | GATGACACGTTTTGTTGTAACTAAATATACCCCC         | 595                    | 94 °C 58 °C 72 °C 45 s     |            |
| ureC        | GCTTCTGTTGTTGTAAC                          | 317                    | 94 °C 56 °C 72 °C 40 s     |            |
| rfbA        | TCGGAGGAGGCGAGACACCTCTGTTGTTGTA            | 467                    | 94 °C 58 °C 72 °C 45 s     |            |
| zhaA        | ACCGACGAGAAGAATATATGCC                     | 540                    | 94 °C 59 °C 72 °C 45 s     |            |
| ietA        | GCTTCTGTTGTTGTAAC                         | 576                    | 94 °C 50 °C 72 °C 45 s     |            |
| sulI        | CGCGGTTGGGTATCGGACGCC                     | 433                    | 94 °C 54 °C 72 °C 45 s     |            |
| bldDEC      | ATGCACTCGACCGAGGCTCT                      | 892                    | 94 °C 55 °C 72 °C 45 s     |            |
| bldRSM1     | GGCAGAAAGGCCCTTGCTCACGA                   | 287                    | 94 °C 55 °C 72 °C 30 s     |            |
| bldCTX-M    | ATGAGCTGTAGAGGCTCTGTAAC                 | 593                    | 94 °C 54 °C 72 °C 45 s     |            |
| bldRGLA1    | AATAGTCATCGTCTGTCATGC                   | 619                    | 94 °C 54 °C 72 °C 45 s     |            |
| bldRSM      | ATGTGCAATAGAAGGCCTCTGCC                     | 516                    | 94 °C 54 °C 72 °C 45 s     |            |

Isolation and identification of *P. mirabilis*. The obtained samples were enriched in peptone water (Oxoid, Hampshire, UK) at 37 °C for 24 h. A loopful from the enriched broth was streaked on XLD, 5% sheep blood agar, MacConkey agar, and TSI (Oxoid, Hampshire, UK), then left incubated at 37 °C for 24–48 h. The identification of suspected colonies was performed according to their culture characters, swarming activity, hemolytic activity, morphological characteristics using Gram's-staining, and biochemical characters as described by Quinn24. Moreover, the identification of *P. mirabilis* was confirmed by the PCR detection of the *atpD* gene as described by Bi25 (Table 2), followed by gene sequencing of the PCR products.

The *atpD* gene sequencing and phylogenetic analyses. Since the retrieved isolates exhibited harmony in their phenotypic and biochemical characteristics: the PCR products of 5 randomly selected isolates were purified with a QIAquick PCR-Product extraction kit (QIAGEN Sciences Inc., Germantown, MD, USA) and sent for direct sequencing using the same set of primers. The sequencing was carried out using the Bigdye Terminator V3.1 cycle sequencing kit (Thermo Fisher Scientific, Waltham, MA, USA), and the retrieved sequences were deposited in the GenBank with accession numbers: MW357650, MW357651, MW357652, MW357653, and MW357654. To detect the sequence identity to GenBank accessions, the BLAST analysis (Basic Local Alignment Search Tool) was done. The phylogenetic tree was generated by the MegAlign module of LasergeneDNASTar version 12.1 using maximum likelihood, neighbor-joining, and maximum parsimony in MEGA626.

Antimicrobial susceptibility testing of *P. mirabilis*. The disc diffusion method was carried out to investigate the antibiotic of the obtained *P. mirabilis* isolates using Mueller-Hinton agar (Oxoid, Hampshire, UK). Fifteen antimicrobial agents were involved; colistin sulfate (CT) (10 μg), cefazidime (CAZ) (30 μg), amoxicillin (AMX) (10 μg), norfloxacin (NOR) (10 μg), piperacillin (PRL) (10 μg), amoxicillin–clavulanic acid (AMC) (30 μg), imipenem (IPM) (10 μg), nalidixic acid (ND) (30 μg), ampicillin (AMP) (10 μg), ceftazidime (30 μg) (CTX), erythromycin (E) (15 μg), ampicillin-sulbactam(SAM) (30 μg), meropenem (MEM) (10 μg), trimethoprim-sulfamethoxazole (SXT) (19:1 μg), and doxycycline (DOX) (10 μg) (Oxoid, UK). The test was performed using E. coli-ATCC 35218 as a control strain. The diameter of the inhibition zone was estimated as described by CLSI27. The phenotypic resistance patterns are categorized into PDR, XDR, and MDR according to Magiorakos28.

Estimation of the biofilm formation in the isolated *P. mirabilis*. Estimation of biofilm formation was carried out in glass test tubes as previously described by Kadam29. Briefly, each *P. mirabilis* strain was inoculated in tryptic soy broth (Oxoid, Hampshire, UK), and left incubated overnight at 28 °C without shaking. Negative control experiments were carried out with sterile broth. After discarding the broth, the incubated tubes were stained with 1% crystal violet (to observe cells attached to the test tube) and were incubated for 15 min. Then, the tubes were washed with sterile distilled water. The test was repeated three times for each strain. Positive results indicated by the formation of purple biofilms.
Table 3. Prevalence of P. mirabilis among the examined birds.

| Bird condition | No of examined birds | Positive for P. mirabilis |
|----------------|----------------------|----------------------------|
|                | No                  | %                          |
| Apparently healthy |                     |                            |
| Alive (n = 20)  | 2                   | 10                         |
| Freshly dead (n = 20) | 4              | 20                         |
| Subtotal     | 6                   | 15 (6/40)                  |
| Diseased     |                     |                            |
| Alive (n = 20)  | 5                   | 25                         |
| Freshly dead (n = 20) | 9              | 45                         |
| Subtotal     | 14                  | 35 (14/40)                 |
| Total        | 80                  | 20 (20/80)                 |

PCR detection of virulence and antimicrobial resistance genes in the retrieved P. mirabilis. The PCR-based detection of ureC, zapA, and rsbA virulence genes and blaTEM, blaCTX, blaoxa-1, sul1, and tetA antimicrobial resistance genes was performed. Extraction of bacterial DNA was carried out according to the descriptions of the QIAamp DNA Mini Kit (QIAGEN Sciences Inc., Germantown, MD, USA/ Cat. No. ID 51326). Accordingly, the reaction volume was 50 μl as follows: 5 μl of 10 × PCR reaction buffer, 1 μl 200 μM (of each dNTP) of dNTP mix (10 mM), 4 μl of bacterial-DNA, 0.4 μl 2 U of Taq DNA Polymerase (5 U/μl), 30 pmol of each used primer (0.1–0.6 μM), and then Sterile ddH2O was added up to 50 μl. Positive control strains (kindly supported by the Biotechnology Center of AHRI, Egypt) were involved in all PCR reactions. Besides, a reaction without a DNA-template was used as a negative control. Oligonucleotides-sequences (Thermo Fisher Scientific, Waltham, MA, USA) and the thermal-cycling protocols are described in Table 2. The agar gel electrophoresis was carried out for the separation of the obtained PCR-products using 1.5% agarose stained with ethidium bromide 0.5 μg/ml and followed by photographing the gel.

Statistical analyses. The obtained findings were analyzed using the Chi-square test (SAS software, version 9.4, SAS Institute, Cary, NC, USA) (Significance-level; P < 0.05). Besides, the correlation coefficient and the non-parametric Wilcoxon rank test were performed using R-software (version 4.0.2; https://www.r-project.org/).

Results

Phenotypic characteristics and prevalence of P. mirabilis in the examined samples. The recovered colonies are red with black center on XLD, pale colonies (non-lactose fermenter) on MacConkey agar, black stained with ethidium bromide 0.5 μg/ml and followed by photographing the gel.

| Bird condition | No of examined birds | Positive for P. mirabilis |
|----------------|----------------------|----------------------------|
|                | No                  | %                          |
| Apparently healthy |                     |                            |
| Alive (n = 20)  | 2                   | 10                         |
| Freshly dead (n = 20) | 4              | 20                         |
| Subtotal     | 6                   | 15 (6/40)                  |
| Diseased     |                     |                            |
| Alive (n = 20)  | 5                   | 25                         |
| Freshly dead (n = 20) | 9              | 45                         |
| Subtotal     | 14                  | 35 (14/40)                 |
| Total        | 80                  | 20 (20/80)                 |

Sequence analysis of the atpD gene. The atpD gene sequencing and the phylogenetic analysis proved that the tested P. mirabilis isolates (n = 5) shared a common ancestor. Moreover, the tested isolates showed high genetic identity to other strains of P. mirabilis such as P. mirabilis strain H14320 of United Kingdom (Accession No. AM942759), P. mirabilis strain BB2000 of China (Accession No. MF576130), P. mirabilis strain BB2000 (Accession No. CP045538) and strain AOUC-001 (Accession No. CP015347) of Italy, and P. mirabilis strain BB2000 of USA (Accession No. CP000422) as illustrated in Fig. 2.

Antibiogram and the phenotypic resistance patterns of the isolated P. mirabilis. The recovered P. mirabilis isolates exhibited remarkable resistance-patterns to various antimicrobial classes including; Penicillins: amoxicillin and penicillin (100%), and piperacillin (77.1%), β-Lactam-β-lactamase-inhibitor combination: ampicillin-sulbactam and amoxicillin-clavulanic acid (71.7%), Sulfonamides: trimethoprim-sulfamethoxazole (100%); Tetracyclines: doxycycline (100%), Quinolones: nalidixic acid (62.8%), Macrolides: erythromycin (62.8%), and Cephalosporins: cepazidime and cefotaxime (57.1%). Moreover, the tested isolates displayed intermediate resistance to Polymyxins: colistin sulfate (51.4%). Besides, the retrieved isolates were sensitive to Fluoroquinolones: norfloxacin (85.7%), and Carbapenems: meropenem (77.1%), and imipenem (74.3%). Furthermore, 8.3% of the tested P. mirabilis isolates (n = 3) were found to be carbapenem-resistant strains (Table 5, Supplementary Table S1, and Fig. 3). Statistically, there is a significant difference (P < 0.05) in the susceptibility of the obtained P. mirabilis isolates to different tested antimicrobial agents. Moreover, the correlation-coefficient between various involved antimicrobial agents was estimated.
Our findings proved a remarkable positive correlations \((r = 0.5–1)\) between: NOR, IPM, and MEM \((r = 0.99)\); E and CAZ \((r = 0.99)\); CTX and CAZ \((r = 0.99)\); SAM, PRL, and CAZ \((r = 0.99)\); AMP, AMX, SXT, AMC, DOX, and CTX \((r = 0.94)\); NA and CT \((r = 0.99)\); AMP, AMX, SXT, AMC, DOX, and CAZ \((r = 0.98)\); CTX and SAM \((r = 0.98)\); SAM and CTX \((r = 0.97)\); PRL and CTX \((r = 0.96)\); E and SAM \((r = 0.96)\); E and PRL \((r = 0.94)\); AMP, AMX, SXT, AMC, DOX, and E \((r = 0.93)\); E and CT \((r = 0.89)\); CTX and CT \((r = 0.87)\); as described in the heatmap (Fig. 4).

The prevalence of biofilm formation among the recovered \(P.\ mirabilis\) strains. Approximately 94.3% (33/35) of the isolated \(P.\ mirabilis\) strains were biofilm producers, while 5.7% (2/35) of the tested strains are non-biofilm producers. Of the biofilm producers \((n = 33)\), 25 strains (75.8%) were strong biofilm producers, 5 strains (15.1%) were moderate biofilm producers, and 3 strains were weak biofilm producers (9.1%) as described in Fig. 5.

Virulence and antimicrobial resistance genes of the recovered \(P.\ mirabilis\) strains. The PCR revealed that the isolated \(P.\ mirabilis\) strains harbored atpD, ureC, rsbA, and zapA virulence genes with a prevalence of 100%, 100%, 94.3%, and 91.4%, respectively. Furthermore, the tested strains harbored \(bla_{TEM}\), \(sul\), \(tet\), \(bla_{CTX-M}\), \(bla_{NDM}\), and \(bla_{KPC}\) antimicrobial-resistance genes with a prevalence of 100%, 100%, 80%, 57.1%, 5.7%, and 2.9%, respectively, as illustrated in Table 6 and Fig. 6. Statistically, there is no significant difference \((P > 0.05)\) in the occurrence of virulence genes among the retrieved \(P.\ mirabilis\) strains, whereas there is a significant difference \((P < 0.05)\) in the frequency of the antimicrobial resistance genes between the tested strains.
**Figure 2.** The phylogenetic analyses were based on the *atpD* gene sequencing. The phylogenetic tree illustrates the genetic relatedness of the retrieved *P. mirabilis* isolates and other relevant isolates deposited in the GenBank database. The tree topology was assessed by bootstrap analysis of 1000 replicates. The bacteria recovered in the present study are marked with solid red circles.

**Table 5.** Antibiogram of the isolated *P. mirabilis* strains (n = 35).

| Antimicrobial classes | Antimicrobial agents | *P. mirabilis* (n = 35) |  |  |  |
|-----------------------|----------------------|-------------------------|---|---|---|
|                       |                      | S                       | I | R |
|                       |                      | N | % | N | % | N | % |
| Fluoroquinolones      | Norfloxacin          | 30 | 85.7 | 2 | 5.7 | 3 | 8.6 |
| Penicillins           | Amoxicillin          | 0 | 0 | 0 | 0 | 35 | 100 |
|                       | Penicillin           | 0 | 0 | 0 | 0 | 35 | 100 |
|                       | Piperacillin         | 3 | 8.6 | 5 | 14.3 | 27 | 77.1 |
| β-Lactam-β-lactamase-inhibitor combinations | Ampicillin-Sulbactam | 3 | 8.6 | 5 | 14.3 | 27 | 77.1 |
|                       | Ampicillin-clavulanic acid | 4 | 11.4 | 4 | 11.4 | 27 | 77.1 |
| Carbapenems           | Meropenem            | 27 | 77.1 | 5 | 14.3 | 3 | 8.6 |
|                       | Imipenem             | 26 | 74.3 | 6 | 17.1 | 3 | 8.6 |
| Cephalosporins        | Cefotaxime           | 5 | 14.3 | 10 | 28.6 | 20 | 57.1 |
|                       | Ceftazidime          | 6 | 17.1 | 9 | 25.7 | 20 | 57.1 |
| Sulfonamides          | Trimethoprim-Sulfamethoxazole | 0 | 0 | 0 | 0 | 35 | 100 |
| Quinolones            | Nalidixic acid       | 0 | 0 | 13 | 37.1 | 22 | 62.8 |
| Tetracyclines         | Doxycycline          | 0 | 0 | 0 | 0 | 35 | 100 |
| Macrolides            | Erythromycin         | 3 | 8.6 | 10 | 28.6 | 22 | 62.8 |
| Polymyxins            | Colistin sulfate     | 3 | 8.6 | 18 | 51.4 | 14 | 40 |

Chi square: 219.73, P < 0.0001

---

www.nature.com/scientificreports/
The correlation between the phenotypic and genotypic multidrug-resistance patterns in *P. mirabilis*. Our findings revealed that 31.4% (11/35) of the retrieved *P. mirabilis* strains are extensively drug-resistant (XDR: resistant to ≥ one agent in all but ≤ two antimicrobial classes) to 8 antimicrobial classes (Penicillins: amoxicillin, ampicillin, and piperacillin, β-Lactam-β-lactamase inhibitor combination: ampicillin-sulbactam, and amoxicillin-clavulanic acid, Cephalosporins: cefotaxime, and ceftazidime, Sulfonamides: trimethoprim-Sulfamethoxazole, Tetracyclines: doxycycline, Quinolones: nalidixic acid, Macrolides: erythromycin, and Polymyxins: colistin sulfate) and harbored *bla*<sub>TEM</sub>, *bla*<sub>OXA-1</sub>, *bla*<sub>CTX-M</sub>, *tetA*, and *sul*<sub>1</sub> resistance genes. Furthermore, 22.8% (8/35) of the tested strains revealed multidrug resistance (MDR: resistant to ≥ one agent in ≥ 3 antimicrobial classes) to 3 antimicrobial classes (Tetracyclines: doxycycline, Penicillins: amoxicillin, and ampicillin, and Sulfonamides: trimethoprim-sulfamethoxazole) and possessed *tetA*, *bla*<sub>TEM</sub>, and *sul*<sub>1</sub> resistance genes. Besides, 17.1% (6/35) of the tested strains are MDR to 7 antimicrobial classes (Penicillins: amoxicillin, ampicillin, and piperacillin, β-Lactam-β-lactamase inhibitor combinations, Cephalosporins: cefotaxime, and ceftazidime, Sulfonamides: trimethoprim-Sulfamethoxazole, Tetracyclines: doxycycline, Quinolones: nalidixic acid, and Macrolides: erythromycin), and carried *bla*<sub>TEM</sub>*, *bla*<sub>OXA-1</sub>**, *bla*<sub>CTX-M</sub>*, *tetA*, and *sul*<sub>1</sub> resistance genes. Moreover, 14.2% (5/35) of the tested strains are MDR to 4 antimicrobial classes (Penicillins: amoxicillin, ampicillin, and

**Figure 3.** The heat-map illustrates the different degrees of susceptibility (sensitive, intermediate, and resistant) of the retrieved *P. mirabilis* to different tested antimicrobial agents.

**Figure 4.** The heat-map illustrates the correlation-coefficient (r) among various antimicrobial agents. Blue and red color points to the positive and negative correlations, respectively.
piperacillin, β-Lactam-β-lactamase inhibitor combinations, Sulfonamides: trimethoprim-Sulfamethoxazole, and Tetracyclines: doxycycline) and harbored blaTEM, blaOXA-1, tetA, and sul1 resistance genes.

Unfortunately, 3 strains are Pan-drug resistant (PDR) to all the tested 10 antimicrobial classes (Carbapenems: imipenem and meropenem, Fluoroquinolones: norfloxacin, Penicillins: amoxicillin, ampicillin, and piperacillin, β-Lactam-β-lactamase inhibitor combinations, Sulfonamides: trimethoprim-Sulfamethoxazole, Cephalosporins: cefotaxime, and ceftazidime, Tetracyclines: doxycycline, Quinolones: nalidixic acid, Macrolides: erythromycin, and Polymyxins: colistin sulfate); two strains harbored blaTEM, blaOXA-1, blaCTX-M, blaNDM-1, tetA and sul1 genes,
while one strain harbored bla_{TEM}, bla_{OXA-1}, bla_{CTX-M}, bla_{KPC}, tetA, and sul1 resistant genes as described in Table 7 and Fig. 7.

The correlation-coefficient (r) was estimated between different tested antimicrobial agents and the antimicrobial resistance genes. Our findings provided a remarkable positive correlations between: (r = 0.5–1), sul1 gene and SXT (r = 1); tetA gene and DOX (r = 1); bla_{CTX-M} gene and CTX (r = 1); bla_{TEM} gene and CAZ (r = 0.99); bla_{OXA-1} gene, MEM, and IPM (r = 0.99); bla_{NDM-1} gene, MEM, and IPM (r = 0.99); bla_{TEM} gene, AMX, and AMP (r = 0.99); bla_{OXA-1} gene, AMC, AMX, and AMP (r = 0.97); bla_{OXA-1} gene and PRL (r = 0.96); bla_{OXA-1} gene and SAM (r = 0.95); bla_{OXA-1} gene and CAZ (r = 0.90); bla_{OXA-1} gene and CTX (r = 0.84); bla_{CTX-M} gene and bla_{OXA-1} gene (r = 0.84); as illustrated in the heat-map (Fig. 8).

### Discussion

*Proteus mirabilis* is frequently incriminated in food-borne infections and urinary tract infections in humans. Few studies are concerning the emergence of *P. mirabilis* in birds. The current study was directed to investigate the prevalence, atpD gene sequencing, antimicrobial-resistance profiles, PCR-based detection of virulence genes (ureC, zapA, and rsbA), and antimicrobial resistance genes (bla_{TEM}, bla_{CTX-M}, bla_{KPC}, bla_{NDM-1}, bla_{OXA-1}, sul1, and tetA) of emerging *P. mirabilis* in ducks.

The bacteriological examination evidenced that the prevalence of *P. mirabilis* in the examined samples was 14.6% (35/240). Besides, there is no ambivalence in the phenotypic characteristics of the retrieved *P. mirabilis* strains that revealed a significant harmony between the isolates: red colonies with black center on XLD, pale colonies (non-lactose fermenter) on MacConkey agar, black colonies on TSI, and undergo a characteristic swarm- ing activity. Biochemically: the retrieved isolates are positive for catalase, H₂S, urease, methyl-red, and citrate utilization tests, whereas they are negative for oxidase, lactose fermentation, indole, and Voges-Proskauer tests. These results are in agreement with those obtained by Lei⁶ and Reich⁷. In the present study, *P. mirabilis* was isolated from the internal organs of the examined birds in a pure form suggesting that the retrieved isolates were the primary bacterial cause of these infections in ducks. These results were supported by the previous findings that were reported by Barbour³⁶ and Yeh³⁷. *P. mirabilis* is a ubiquitous pathogen widely distributed in the environment,³⁸ *P. mirabilis* is an opportunistic pathogen that is incriminated in various infections in humans, animals, and poultry. Recently, several studies reported the emergence of *P. mirabilis* in food-producing animals, especially poultry⁸⁶,³⁸,³⁹.

In the present study, *P. mirabilis* could be isolated from the internal organs of both apparently healthy and diseased birds. *P. mirabilis* is an opportunistic microorganism that normally inhabits the alimentary tract of birds, animals, and humans. The microorganism could escape from the intestinal tract and reach other internal organs. Thus, it could be responsible for other illnesses associated with the spread of *P. mirabilis* to other internal organs, and in severe cases, it could cause sepsis. In the meantime, the development of the clinical signs depends mainly on the onset of the disease as well as the immune status of the bird⁴⁰.

The atpD gene phylogenetic analysis revealed that the tested *P. mirabilis* isolates (n = 5) are shared a common ancestor. Besides, they exhibited high genetic identity with other *P. mirabilis* strains of human origin that were previously isolated in Italy⁴¹,⁴², China⁴³, USA⁴⁴, and United Kingdom⁴⁵. Our findings conceived the epidemiological map and emphasized the zoonotic impact of *P. mirabilis* that is considered a public health threat.

Concerning the in-vitro antimicrobial-resistance profiles, the recovered *P. mirabilis* strains showed remarkable resistance-patterns to penicillins, β-Lactam β-lactamase-inhibitor combinations, cephalosporins, sulfonamides, tetracyclines, macrolides, and quinolones. The development of such resistant strains reflected as a public health threat. Moreover, the retrieved strains were sensitive to norfloxacin (85.7%), meropenem (77.1%), and imipenem (74.3%). Our findings are consistent with those reported by Wong⁴⁶ and Nahar⁴⁷. The improper application of antimicrobial agents in the poultry industry and the ability of *P. mirabilis* to acquire the antimicrobial-resistant genes from other resistant pathogens are the main causes of the emergence of these MDR-strains. Unfortunately, *P. mirabilis* could resist various antimicrobial classes due to the presence of chromosomal antibiotic-resistant genes as well as the resistant-plasmids³⁷.

The biofilm assay revealed that 94.3% (33/35) of the isolated *P. mirabilis* strains are biofilm producers. Our findings are nearly agreed with those reported by Pathirana³⁰ and Sun⁵¹. The correlation-coefficient (r) was estimated between different tested antimicrobial agents and the antimicrobial resistance genes as described in Table 7 and Fig. 7.

The PCR proved that the recovered *P. mirabilis* strains are virulent and harbored atpD, ureC, rsbA, and zapA virulence genes with a prevalence of 100%, 90.8%, and 91.4%, respectively. Our findings are nearly agreed with those reported by Pathirana³⁰ and Sun⁵¹. The atpD gene is encoded for ATP synthase β-subunit for the production of ATP from ADP. The atpD gene is more conservative in *Proteus* species when compared with 16S rRNA³⁷. Infections caused by *P. mirabilis* are controlled by several virulence-determinants that are regulated by specific virulence genes. IgA-degrading proteases are commonly accompanied by the pathogenic strains of *P. mirabilis*. ZapA-protease could degrade IgG, IgA, and IgA2. It is regulated by the zapA gene. *P. mirabilis* is frequently incriminated in urinary tract infections that are mediated by stone-formation due to the release of urease enzyme. Urease is a metalloenzyme that acts by increasing the pH of urine that induces crystal formation. The urease production is controlled by the ureC gene. Besides, the characteristic swarming activity of *P. mirabilis* is encoded by the rsbA gene. The rsbA gene expresses a membrane sensor that induces the production of extracellular polysaccharides. Also, it regulates the swarming phenomena and enhances the biofilm formation by *P. mirabilis*²⁵,⁵⁰,⁵³.
| No. of strains | %  | Type of resistance | In-vitro phenotypic resistance | The antimicrobial resistance genes |
|---------------|----|--------------------|-------------------------------|----------------------------------|
| 11            | 31.4 | XDR               | Penicillins: amoxicillin, ampicillin, and piperacillin | \(\text{bla}_{TEM}, \text{bla}_{OXA-1}, \text{bla}_{CTX-M}, \text{tet}A, \text{and sul}1\) |
|               |      |                   | \(\beta\)-Lactam-\(\beta\)-lactamase inhibitor combinations: |                                   |
|               |      |                   | ampicillin-sulbactam, and amoxicillin-clavulanic acid |                                   |
|               |      |                   | Cephalosporins: cefotaxime, and ceftazidime. |                                   |
|               |      |                   | Sulfonamides: trimethoprim-Sulfamethoxazole |                                   |
|               |      |                   | Tetracyclines: doxycycline |                                   |
|               |      |                   | Quinolones: nalidixic acid |                                   |
|               |      |                   | Macrolides: erythromycin |                                   |
|               |      |                   | Polymyxins: colistin sulfate |                                   |
| 8             | 22.8 | MDR               | Penicillins: amoxicillin, and ampicillin | \(\text{bla}_{TEM}, \text{tet}A, \text{and sul}1\) |
|               |      |                   | Tetracyclines: doxycycline |                                   |
|               |      |                   | Sulfonamides: trimethoprim-Sulfamethoxazole |                                   |
| 6             | 17.1 | MDR               | Penicillins: amoxicillin, ampicillin, and piperacillin | \(\text{bla}_{TEM}, \text{bla}_{OXA-1}, \text{bla}_{CTX-M}, \text{tet}A, \text{and sul}1\) |
|               |      |                   | \(\beta\)-Lactam-\(\beta\)-lactamase inhibitor combinations: |                                   |
|               |      |                   | Cephalosporins: cefotaxime, and ceftazidime |                                   |
|               |      |                   | Sulfonamides: trimethoprim-Sulfamethoxazole |                                   |
|               |      |                   | Tetracyclines: doxycycline |                                   |
|               |      |                   | Quinolones: nalidixic acid |                                   |
|               |      |                   | Macrolides: erythromycin |                                   |
| 5             | 14.2 | MDR               | Penicillins: amoxicillin, ampicillin, and piperacillin | \(\text{bla}_{TEM}, \text{bla}_{OXA-1}, \text{tet}A, \text{and sul}1\) |
|               |      |                   | \(\beta\)-Lactam-\(\beta\)-lactamase inhibitor combinations: |                                   |
|               |      |                   | Sulfonamides: trimethoprim-Sulfamethoxazole |                                   |
|               |      |                   | Tetracyclines: doxycycline |                                   |
| 2             | 5.7  | PDR               | Penicillins: amoxicillin, ampicillin, and piperacillin | \(\text{bla}_{TEM}, \text{bla}_{OXA-1}, \text{bla}_{CTX-M}, \text{bla}_{NDM-1}, \text{tet}A, \text{and sul}1\) |
|               |      |                   | \(\beta\)-Lactam-\(\beta\)-lactamase inhibitor combinations: |                                   |
|               |      |                   | Cephalosporins: cefotaxime, and ceftazidime |                                   |
|               |      |                   | Fluroquinolones: Norfloxacin |                                   |
|               |      |                   | Sulfonamides: trimethoprim-Sulfamethoxazole |                                   |
|               |      |                   | Tetracyclines: doxycycline |                                   |
|               |      |                   | Quinolones: nalidixic acid |                                   |
|               |      |                   | Macrolides: erythromycin |                                   |
|               |      |                   | Polymyxins: colistin sulfate |                                   |
|               |      |                   | Carbapenems: imipenem and meropenem |                                   |
| 2             | 5.7  | MDR               | Penicillins: amoxicillin, ampicillin, and piperacillin | \(\text{bla}_{TEM}, \text{bla}_{OXA-1}, \text{tet}A, \text{and sul}1\) |
|               |      |                   | \(\beta\)-Lactam-\(\beta\)-lactamase inhibitor combinations: |                                   |
|               |      |                   | Sulfonamides: trimethoprim-Sulfamethoxazole |                                   |
|               |      |                   | Tetracyclines: doxycycline |                                   |
|               |      |                   | Quinolones: nalidixic acid |                                   |
|               |      |                   | Macrolides: erythromycin |                                   |
Continued
Concerning the correlation between the phenotypic and genotypic antimicrobial resistance patterns; our findings revealed that 31.4% (11/35) of the retrieved *P. mirabilis* strains are XDR to 8 antimicrobial classes, and harbored *bla*\(_{\text{TEM}}\), *bla*\(_{\text{OXA-1}}\), *bla*\(_{\text{CTX-M}}\), *tetA*, and *sul1* genes. Moreover, 22.8% (8/35) of the tested strains are MDR to 3 antimicrobial classes and possessed *bla*\(_{\text{TEM}}\), *tetA*, and *sul1* genes. Besides, 17.1% (6/35) of the tested strains are MDR to 7 antimicrobial classes and harbored *bla*\(_{\text{TEM}}\), *bla*\(_{\text{OXA-1}}\), *bla*\(_{\text{CTX-M}}\), *tetA*, and *sul1* genes. The Extended-spectrum β-lactamases (ESBLs) were reported for the first time in 1983\(^{54}\). ESBLs are responsible for the hydrolysis of Broad-spectrum β-lactam antibiotics including penicillins, piperacillin, and cephalosporins. ESBLs are frequently produced by *Enterobacteriaceae*. Recently, *P. mirabilis* strains reported harboring various acquired antimicrobial resistance genes. The high prevalence of the *bla*\(_{\text{TEM}}\) gene among the recovered *P. mirabilis* strains enabling them to resist penicillins (amoxicillin and ampicillin). Moreover, the resistance to cephalosporins (ceftaxime, and cefazidime) is mediated by the presence of the *bla*\(_{\text{CTX-M}}\) gene. The resistance to piperacillin is mainly attributed to the *bla*\(_{\text{OXA-1}}\) gene which also promoting the resistance to cephalosporins. Besides, both *bla*\(_{\text{OXA-1}}\) and

| No. of strains | %   | Type of resistance | In-vitro phenotypic resistance | The antimicrobial resistance genes |
|---------------|-----|--------------------|--------------------------------|----------------------------------|
| 1             | 2.9 | PDR                | Penicillins: amoxicillin, ampicillin, and piperacillin | *bla*\(_{\text{TEM}}\), *bla*\(_{\text{OXA-1}}\), *bla*\(_{\text{CTX-M}}\), *tetA*, and *sul1* |
|               |     |                    | β -Lactam- β-lactamase inhibitor combinations |                                |
|               |     |                    | Cephalosporins: cefotaxime, and cefazidime |                                |
|               |     |                    | Fluroquinolones: Norfloxacin |                                |
|               |     |                    | Sulfonamides: trimethoprim-Sulfamethoxazole |                                |
|               |     |                    | Tetracyclines: doxycycline |                                |
|               |     |                    | Quinolones: nalidixic acid |                                |
|               |     |                    | Macrolides: erythromycin |                                |
|               |     |                    | Polymyxins: colistin sulfate |                                |
|               |     |                    | Carbapenems: imipenem and meropenem |                                |

Table 7. The correlation between phenotypic and genotypic resistance patterns among the retrieved *P. mirabilis* (*n* = 35).

Figure 7. Illustrates the distribution of PDR, XDR, and MDR among the retrieved *P. mirabilis* strains.
CTX-M genes synergistically enable *P. mirabilis* to resist the β-Lactam-β-lactamase-inhibitor-combinations.\(^{55,56}\) In addition, *P. mirabilis* is frequently resistant to tetracyclines and sulfonamides due to the presence of *tetA* and *sul1* genes, respectively. On the other hand, *P. mirabilis* is usually susceptible to fluoroquinolones such as norfloxacin.\(^{57}\) The polymyxins exert their effect by increasing the permeability of the Gram-negative bacterial cell membrane through displacing Mg\(^{2+}\) and Ca\(^{2+}\) from the lipid A content of LPS that results in leakage of the cell contents. The resistance to polymyxins is common in the mutant *P. mirabilis* due to the alteration of LPS that is controlled by the expression of the *epiC* gene and the modification of the L-Ara4N. However, several previous studies reported the sensitivity of some *P. mirabilis* isolates to polymyxins, especially those of animal origin as reported by Sun.\(^{51}\) The *epiC* gene may be present but not expressed. Besides, the alterations of the LPS in the cell envelop occurs only in the mutant strains and varies among different strains of *P. mirabilis* as previously reported by McCoy.\(^{58}\)

In the present study, three strains are carbapenem-resistant as well as PDR to all the tested ten antimicrobial classes and are sharing *blaTEM*, *blaOXA-1*, *blaCTX-M*, *tetA*, and *sul1* genes. Of them, two strains harbored the *blaNDM-1* gene, and one strain carried the *blaKPC* gene. Globally, the emergence of carbapenem-resistance in *P. mirabilis* is relatively low; however, it inclines to increase over time. The carbapenem-resistance is attributed to the presence of *blaNDM-1* and *blaKPC* genes. The existence of the *blaKPC* gene in *P. mirabilis* was recorded for the first time in a diabetic patient in the USA in 2008\(^{59}\), followed by China in 2010\(^{60}\), and Brazil in 2015.\(^{61}\) Moreover, the *blaNDM-1* is recognized for the first time in *P. mirabilis* strain retrieved from urinary infection in France in 2012\(^{62}\) and followed by China in 2015.\(^{63}\)

Concerning the correlation between the antimicrobial resistance genes and the virulence determinants, a previous study that was reported by Filipiak revealed an inverted correlation between the virulence factors and the presence of the resistance genes in the retrieved *P. mirabilis* strains. However, in the present study, the majority of the screened virulence genes were found in the recovered isolates. Besides, there is no significant difference in the distribution of the virulence genes among the retrieved isolates either the susceptible or the antimicrobial-resistant strains. These findings suggest that the *P. mirabilis* pathogenicity is not affected by the presence of antimicrobial resistance genes.

**Study limitations.** Multilocus sequence typing (MLST) should be carried out to illustrate the genetic relatedness among the recovered *P. mirabilis* strains.

In conclusion, to the best of our knowledge, this is the first report regarding the emergence of XDR and MDR-*P. mirabilis* in ducks. *P. mirabilis* is more prevalent in diseased birds than the apparently healthy ones, and the liver is the most prominent infected organ. *P. mirabilis* is a common biofilm-producing pathogen. The recovered *P. mirabilis* isolates commonly harbor the *atpD*, *ureC*, *zapA*, and *rsbA* virulence genes. The retrieved *P. mirabilis* strains are extensively drug-resistant (XDR) or multidrug-resistant (MDR) to several antimicrobial classes (penicillins, β-Lactam-β-lactamase-inhibitor-combinations, cephalosporins, sulfonamides, tetracyclines, quinolones, macrolides, and polymyxins), and commonly harbored *blaTEM*, *blaOXA-1*, *blaCTX-M*, *tetA*, and *sul1* antimicrobial...
resistance genes. In-vitro, norfloxacin exhibited promising antibacterial activity against the recovered XDR and MDR-*P. mirabilis*. Furthermore, the emergence of carbapenem-resistant (harbored either *bla*<sub>KPC</sub> or *bla*<sub>NDM</sub> genes) and PDR-strains constitutes a threat alarm that indicates a complicated treatment of the diseases caused by such superbugs. Accordingly, it endorses the incessant surveillance of antimicrobial susceptibility testing as well as the limited and appropriate use of antibiotics in health and veterinary practices.

Received: 23 December 2020; Accepted: 19 April 2021
Published online: 04 May 2021

**References**

1. O’Hara, C. M., Brenner, F. W. & Miller, J. M. Classification, identification, and clinical significance of *Proteus, Providencia*, and *Morganella*. *Clin. Microbiol. Rev.* 13, 534–546 (2000).

2. Chen, C. Y. et al. *Proteus mirabilis* urinary tract infection and bacteremia: Risk factors, clinical presentation, and outcomes. *J. Microbiol. Immunol. Infect.* 45, 228–236 (2012).

3. Jansen, A. M., Lockattell, C. V., Johnson, D. E. & MObley, H. L. T. Visualization of *Proteus mirabilis* morphotypes in the urinary tract: The elongated swarmer cell is rarely observed in ascending urinary tract infection. *Infect. Immun.* 71, 3607–3613 (2003).

4. Shi, X. et al. Comparative screening of digestion tract toxic genes in *Proteus mirabilis*. *PLoS ONE* 11, e0151873 (2016).

5. Wang, Y. et al. An outbreak of *Proteus mirabilis* food poisoning associated with eating stewed pork balls in brown sauce, Beijing. *Food Control* 21, 302–305 (2010).

6. Lei, C. W. Characterization of SXT/R391 integrative and conjunctive elements in *Proteus mirabilis* isolates from food-producing animals in China. *Antimicrob. Agents Chemother.* 60, 1935–1938 (2016).

7. Reich, F., Atanassova, V. & Klein, G. Extended-spectrum β-lactamase- and ampC-producing *Enterobacteriaceae* in healthy broiler chickens, Germany. *Emerg. Infect. Dis.* 19, 1253–1259 (2013).

8. Olontolita, O. S., Fahrenfeld, N. & Pruden, A. Antibiotic resistance profiles among mesophilic aerobic bacteria in Nigerian chicken litter and associated antibiotic resistance genes. *Poult. Sci.* 94, 862–874 (2015).

9. Makharrat, R. R. et al. Antibiogram and genetic characterization of carbapenem-resistant Gram-negative pathogens incriminated in healthcare-associated infections. *Infect. Drug Resist.* 13, 3991–4002 (2020).

10. Algammal, A. M., Wahdan, A. & Elhaig, M. M. Potential efficiency of conventional and advanced approaches used to detect *Mycobacterium bovis* in cattle. *Microb. Pathog.* 134, 103574 (2019).

11. El-Sayed, M. E., Algammal, A. M., Abouel-Atta, M. E., Mabrok, M. & Emam, A. M. Pathogenicity, genetic typing, and antibiotic sensitivity of *Vibrio algolysisicus* isolated from *Oreochromis niloticus* and *Tilapia zillii*. *Rev. Med. Vet.* 170(4–6), 80–86 (2019).

12. Algammal, A. M. et al. Molecular typing, antibiogram and PCR-RFLP based detection of *Aeromonas hydrophila* complex isolated from *Oreochromis niloticus*. *Pathogens* 9, 238 (2020).

13. Algammal, A. M. et al. Prevalence, the antibiogram and the frequency of virulence genes of the most predominant bacterial pathogens incriminated in calf pneumonia. *AMB Express* 10, 1–8 (2020).

14. Algammal, A. M. et al. Genes encoding the virulence and the antimicrobial resistance in enterotoxicogenic and shiga-toxigenic *E. coli* isolated from diarrheal calves. *Toxins* 12, 382 (2020).

15. Abolghait, S. K., Fathi, A. G., Youssef, F. M. & Algammal, A. M. Methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from chicken meat and giblets often produces staphylococcal enterotoxin B (SEB) in non-refrigerated raw chicken livers. *Int. J. Food Microbiol.* 328, 108669 (2020).

16. Enany, M. E. et al. The occurrence of the multidrug resistance (MDR) and the prevalence of virulence genes and QACs resistance genes in *E. coli* isolated from environmental and avian sources. *AMB Express* 9, 1–9 (2019).

17. Algammal, A. M., Enany, M. E., El-Tarabili, R. M., Ghobashy, M. O. I. & Helmy, Y. A. Prevalence, antimicrobial resistance profiles, virulence and enterotoxin-determinant genes of MRSA isolated from subclinical bovine mastitis samples in Egypt. *Pathogens* 9, 1–11 (2020).

18. Algammal, A. M. et al. Emerging MDR-*Pseudomonas aeruginosa* in fish commonly harbor oprL and toxA virulence genes and bla TEM, bla CTX-M, and tetA antibiotic-resistance genes. *Sci. Rep.* 10, 1–12 (2020).

19. Uzunović, S., Ibrahimagić, A., Hodžić, D. & Bedenić, B. Molekularna epidemiologija i anti-antimikrobnja osjetljivost kliničkih izolata *Proteus spp.* Koji produciranju AmpC-βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββbeta-laktama proširenog spektara djelovanja u Zeničko-Dobojskom kantonu, Bosna i Hercegovina. *Med. Glas.* 13, 103–112 (2016).

20. Li, X. et al. SXT/R391 integrative and conjunctive elements in *Proteus* species reveal abundant genetic diversity and multidrug resistance. *Sci. Rep.* 6, 1–9 (2016).

21. Tonkić, M. et al. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing *Proteus mirabilis* strains in southern Croatia. *J. Med. Microbiol.* 59, 1185–1190 (2010).

22. Naas, T., Zerbi, M., Gurlich, D. & Nordmann, P. Integration of a transposon Tn1-encoded inhibitor-resistant β-lactamase gene, blaTEM-67 from *Proteus mirabilis*, into the *Escherichia coli* chromosome. *Antimicrob. Agents Chemother.* 47, 19–26 (2003).

23. Li, X. & MObley, H. L. T. Vaccines for *Proteus mirabilis* in urinary tract infection. *Int. J. Antimicrob. Agents* 19, 461–465 (2002).

24. Quinn, P. J., Markey, B. K., Carter, M. E., Donnelly, W. J. & Leonard, F. C. Bacterial causes of bovine mastitis. In *Veterinary Microbiology and Microbial Disease* 465–479 (Blackwell Science, New York, 2002).

25. Bi, S. L., Tang, S. Z., Wu, X. Y. & Chen, S. Y. Quantitative detection of *Proteus* species by real-time polymerase chain reaction using *SYBR Green I* *Ann. Microbiol.* 63, 1205–1208 (2013).

26. Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kuma, S. MEGA6: Molecular evolutionary genetics analysis version 6.0. *Mol. Biol. Evol.* 30, 2725–2729 (2013).

27. CLSI. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: 27th ed 424 information supplement. *CLSI Doc. M100-S20* (2017).

28. Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 18, 268–281 (2012).

29. Kadam, S. R. et al. Diversity assessment of *Listeria monocytogenes* biofilm formation: Impact of growth condition, serotype and strain origin. *Int. J. Food Microbiol.* 165, 259–264 (2013).

30. Pathirana, H. N. K. S., De Silva, B. C. J., Wimalasena, S. H. M. P., Hossain, S. & Heo, G. J. Comparison of virulence genes in *Proteus* species isolated from human and pet turtle. *Ir. J. Vet. Res.* 19, 48–52 (2018).

31. Randall, L. P., Cosles, S. W., Osborn, M. K., Piddock, L. J. V. & Woodward, M. J. Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of *Salmonella enterica* isolated from humans and animals in the UK. *J. Antimicrob. Chemother.* 53, 208–216 (2004).

32. Ibebwe, A. M., Murrinda, S. E. & Graves, A. K. Genetic diversity and antimicrobial resistance of *Escherichia coli* from human and animal sources uncovers multiple resistances from human sources. *PLoS ONE* 6, e20819 (2011).

https://doi.org/10.1038/s41598-021-88861-w
33. Xia, Y., Liang, Z., Su, X. & Xiong, Y. Characterization of carbapenemase genes in Enterobacteriaceae species exhibiting decreased susceptibility to carbapenems in a university hospital in Chongqing, China. Ann. Lab. Med. 32, 270–275 (2012).

34. Archambault, M. et al. Molecular characterization and occurrence of extended-spectrum β-lactamase resistance genes among Salmonella enterica serovar corvallis from Thailand, Bulgaria, and Denmark. Microb. Drug Resist. 12, 192–198 (2006).

35. Colom, K. et al. Simple and reliable multiplex PCR assay for detection of blaTEM, blabHV and blaxOXA-1 genes in Enterobacteriaceae. FEMS Microbiol. Lett. 223, 147–151 (2003).

36. Barbou, E. K. et al. Comparison of phenotypic and virulence genes characteristics in human and chicken isolates of Proteus mirabilis. Pathog. Glob. Health 106, 352–357 (2012).

37. Yeh, H. Y., Line, J. E. & Hinton, A. Molecular analysis, biochemical characterization, antimicrobial activity, and immunological analysis of Proteus mirabilis isolated from broilers. J. Food Sci. 83, 770–779 (2018).

38. Ran, P., Rao, V., Rao, S., Subramanyam, K. V. & Srinivas, K. Prevalence and virulence gene profiles of Proteus mirabilis isolated from animal, human and water samples in Krishna District, Andhra Pradesh, India. Pharma Innov. J. 8, 19–23 (2019).

39. Liu, M. C. et al. 10′(Z), 13′(E)-heptadecadienylhydroquinone inhibits swarming and virulence factors and increases polymyxin B susceptibility in Proteus mirabilis. PLoS ONE 7(9), e45563. https://doi.org/10.1371/journal.pone.0045563 (2012).

40. Armbruster, C. E., Holley, R. H. T. & Pearson, M. M. Pathogenesis of Proteus mirabilis Infection. EcoSal Plus https://doi.org/10.1128/ecosal-ESP-0009-2017 (2018).

41. Di Pilato, V. et al. Complete genome sequence of the first KPC-type carbapenemase-positive Proteus mirabilis strain from a bloodstream infection. Genome Announc. https://doi.org/10.1128/genomeA.00607-16 (2016).

42. Bittar, I. et al. Complete genome and plasmids sequences of a clinical Proteus mirabilis isolate producing plasmid mediated ndm-1 from Italy. Microorganisms 8, 339 (2020).

43. Rie, L., Fang, M., Li, Z., Wang, M. & Xu, H. Identification and characterization of new resistance-conferring SG1Is (Salmonella Genomic Island 1) in Proteus mirabilis. Front. Microbiol. 9, 3172 (2018).

44. Sullivan, N. L., Septer, A. N., Fields, A. T., Wenren, L. M. & Gibbs, K. A. The complete genome sequence of Proteus mirabilis Strain BB2000 reveals differences from the P. mirabilis reference strain. Genome Announc. 1, 5. https://doi.org/10.1128/genomeA.00024-13 (2013).

45. Pearson, M. M. et al. Complete genome sequence of uprootogenic Proteus mirabilis, a master of both adherence and motility. J. Bacteriol. 190, 4027–4037 (2008).

46. Wong, M. H. Y., Wan, H. Y. & Chen, S. Characterization of multidrug-resistant Proteus mirabilis isolated from chicken carcasses. Foodborne Pathog. Dis. 10, 177–181 (2013).

47. Nahar, A. Multidrug resistant-Proteus Mirabilis isolated from chicken droppings in commercial poultry farms: bio-security concern and emerging public health threat in Bangladesh. J. Biosaf. Heal. Educ. 2017. https://doi.org/10.4172/2332-0893.1000120 (2014).

48. Kwiecinska-Piróg, J., Bogiel, T., Skowron, K., Wieckowska, E. & Gospodarek, E. Mechanizmy warunkujące opornosc biofilmow bakteryjnych na czynniki antymikrobialne. Biotechnologia 76, 40–52 (2007).

49. Jacobsen, S. M. & Shirliff, M. E. Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence 2, 460–465 (2011).

50. Sun, Y. et al. Association among biofilm formation, virulence gene expression, and antibiotic resistance in Proteus mirabilis isolates from diarrhetic animals in Northeast China. BMC Vet. Res. 16, 176 (2020).

51. Walker, K. E., Moghaddame-Jafari, S., Lockell, C. V., Johnson, D. & Belas, R. ZapA, the IgA-degrading metalloprotease of Proteus mirabilis, is a virulence factor expressed specifically in swarmers cells. Mol. Microbiol. 32, 825–836 (1999).

52. Hussein, E. I. et al. Assessment of pathogenic potential, virulent genes profile, and antibiotic susceptibility of Proteus mirabilis from urinary tract infection. Int. J. Microbiol. 20, 20. https://doi.org/10.1155/2020/1231807 (2020).

53. Knott, H., Shah, P., Kremery, V., Antal, M. & Mitsushashi, S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11, 315–317 (1983).

54. Bidet, P., Verdet, C., Gautier, V., Bingen, E. & Arlet, G. First description of DHA-1 ampC β-lactamase in Proteus mirabilis. Clin. Microbiol. Infect. 11, 591–592 (2005).

55. Schultz, E. et al. Survey of multidrug resistance integrative mobilizable elements SG1 and PG11 in Proteus mirabilis in humans and dogs. J. Antimicrob. Chemother. 70, 2543–2546 (2015).

56. Yung, D. et al. The first detection of CTX-M-14 extended-spectrum β-lactamase among diverse β-lactamase-producing Proteus mirabilis clinical isolates. Diagn. Microbiol. Infect. Dis. 54, 237–239 (2006).

57. McCoy, A. J., Liu, H., Falla, T. J. & Gunn, J. S. Identification of Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides. Antimicrob. Agents Chemother. 45, 2030–2037 (2001).

58. Tiibetts, R., Frye, J. G., Marschall, J., Warren, D. & Dunne, W. Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC β-lactamase in P. mirabilis. J. Clin. Microbiol. 46, 3080–3083 (2008).

59. Hu, Y. Y. et al. Emergence of Proteus mirabilis harboring bla KPC-2 and qnrD in a Chinese hospital. Antimicrob. Agents Chemother. 56, 2278–2282 (2012).

60. Cabral, A. B., Maciel, M. A. V., Barros, J. F., Antunes, M. M. & Lopes, A. C. S. Detection of blaKPC-2 in Proteus mirabilis in Brazil. Rev. Soc. Bras. Med. Trop. 48, 94–95 (2015).

61. Girlich, D., Dorteit, L., Poreil, L. & Nordmann, P. Integration of the bladm-1 carbapenemase gene into Proteus genomic island 1 (PGI1-PmPEL) in a Proteus mirabilis clinical isolate. J. Antimicrob. Chemother. 70, 98–102 (2015).

62. Qin, S. et al. Emergence of extensively drug-resistant Proteus mirabilis harboring a conjugative NDM-1 plasmid and a novel Salmonella genomic island 1 variant, SG11-Z. Antimicrob. Agents Chemother. 59, 6601–6604 (2015).

63. Filipiak, A. et al. Pathogenic factors correlate with antimicrobial resistance among clinical Proteus mirabilis strains. Front. Microbiol. 11, 579389. https://doi.org/10.3389/fmicb.2020.579389 (2020).

Author contributions
A.M.A Conceptualization; A.M.A, R.M.E, H.R.H, H.F.H, H.R, K.J.A, and N.S.S conducted the experiments. A.M.A and R.M.E drafted the manuscript. A.M.A, R.M.E, H.R.H., K.J.A, H.F.H., H.R and N.S.S did the statistical analysis, investigation, data validation and accuracy, and supervision. A.M.A wrote and revised the manuscript. All authors have revised and approved the final manuscript.

Competing interests
The authors declare no competing interests.
